Floatz logo

ROSOPATAMAB

Metastatic Prostate Cancer

Telix Pharmaceuticals (Innovations) Pty Limitedmonoclonal_antibodyPhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Metastatic Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Sipuleucel-T
Yale University
Phase 2BB
Degarelix
Praful Ravi, MB BCHir, MRCP
Phase 3BB
PIFLUFOLASTAT
Brigham and Women's Hospital
Phase 4BB
Apalutamide
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

ROSOPATAMAB is also rated in:

prostate cancerDormant
B
Indicative ·
63 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
gliomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →